Skip to content
Eptacog alfa (activated)
NovoSeven (eptacog alfa (activated)) is a protein pharmaceutical. Eptacog alfa (activated) was first approved as Novoseven on 1996-02-23. It has been approved in Europe to treat factor VII deficiency, hemophilia a, hemophilia b, and thrombasthenia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemophilia aD006467EFO_0007267D661291251449
Hemophilia bD002836D67116541035
Postpartum hemorrhageD006473O72112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral hemorrhageD002543729
Wounds and injuriesD014947T14.83216
Factor vii deficiencyD005168D68.211113
Coronary artery diseaseD003324I25.111
Myocardial ischemiaD017202EFO_1001375I20-I2511
Blood coagulation disordersD001778EFO_0009314D68.911
Heart valve diseasesD006349EFO_0009551I0811
BurnsD002056T30.011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HemorrhageD006470MP_0001914R58347
Liver cirrhosisD008103EFO_0001422K74.022
ThrombastheniaD013915D69.1111
Severe dengueD019595A9111
Spinal fusionD01312311
StrokeD020521EFO_0000712I63.911
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients88
HemostasisD00648722
Intracranial hemorrhagesD020300EFO_0000551I6211
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiopulmonary bypassD00231511
Factor xi deficiencyD005173D68.111
ShockD012769R57.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEPTACOG ALFA (ACTIVATED)
INNeptacog beta (activated)
Description
NovoSeven (eptacog alfa (activated)) is a protein pharmaceutical. Eptacog alfa (activated) was first approved as Novoseven on 1996-02-23. It has been approved in Europe to treat factor VII deficiency, hemophilia a, hemophilia b, and thrombasthenia.
Classification
Protein
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108334
ChEBI ID
PubChem CID
DrugBank
UNII IDAC71R787OV (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Novoseven - Novo Nordisk
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 916 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
29,647 adverse events reported
View more details